市場調查報告書
商品編碼
1467746
2024-2032年按產品類型、人口統計(成人、兒童)、適應症、最終用戶(診斷/診所、重症監護病房、家庭醫療保健)和地區分類的下一代糖尿病治療和藥物傳輸市場Next Generation Diabetes Therapy and Drug Delivery Market by Product Type, Demographic (Adult Population, Child Population ), Indication, End User (Diagnostic/Clinics, Intensive Care Units, Home Healthcare), and Region 2024-2032 |
IMARC Group年,全球下一代糖尿病治療和藥物輸送市場規模達到98億美元。糖尿病(尤其是第 2 型糖尿病)盛行率的上升、技術的不斷進步以及老年人口的不斷成長是推動市場發展的一些關鍵因素。
下一代糖尿病治療和藥物輸送程序的重點是以微創方式將胰島素引入患者體內,以減少頻繁使用針頭引起皮膚刺激的風險。這種對患者友善的方法旨在透過利用穿戴式感測器、微針和吸入胰島素等創新技術來有效管理疾病,同時降低醫療成本。連續血糖監測系統 (CGMS)、人工胰臟和胰島素貼片等先進療法也被用來改善血糖水平管理,從而最大限度地降低糖尿病相關併發症的風險。此外,該程序還可以輕鬆計算劑量體積,即時檢查血糖水平,並將胰島素無痛地輸送到體內,有助於維持給藥時間。這種療法和藥物傳遞實踐的一些優點包括改善患者的治療效果、提高治療效率以及最大限度地減少患者的糖尿病管理負擔,從而製定更有針對性的治療計劃。
全球市場的主要驅動力是大眾中糖尿病(尤其是第 2 型糖尿病)盛行率的上升。這可以歸因於不健康飲食的增加、久坐的生活方式和體力活動的減少。與此一致的是,根據個人需求、生活方式和治療目標對個人化和以患者為中心的護理的需求不斷增加,導致產品的採用率更高。此外,不斷的技術進步,例如智慧胰島素筆、閉迴路系統和副作用較少的植入式設備的開發,正在為市場提供動力。除此之外,個人對微創和無痛治療選擇的日益重視也是市場成長的重要誘導因素。醫療保健支出的增加以及對基於價值的醫療保健解決方案的更多關注進一步推動了市場。然而,發展中地區日益成長的成本限制、缺乏意識和產品變異性較小是市場成長的主要限制因素。相反,有關預防性醫療保健和早期干預的有利政府舉措和報銷政策的實施正在為市場創造積極的前景。除此之外,越來越多的老年人口更容易罹患慢性病,這對市場產生了有利的影響。促進市場發展的其他一些因素包括快速城市化、對傳統糖尿病治療相關併發症的認知不斷提高、遠距醫療和數位醫療解決方案的日益採用、可支配收入水平的提高以及主要參與者進行的廣泛研發( R&D)活動。
The global next generation diabetes therapy and drug delivery market size reached US$ 9.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 33.5 Billion by 2032, exhibiting a growth rate (CAGR) of 14.23% during 2024-2032. The rising prevalence of diabetes, particularly type-2 diabetes, continual technological advancements, and the growing geriatric population represent some of the key factors driving the market.
Next generation diabetes therapy and drug delivery procedure focuses on the introduction of insulin into the patient's body in a minimally invasive manner to reduce the risk of skin irritation from frequent needle usage. This patient-friendly approach aims to effectively manage the disease while reducing healthcare costs by utilizing innovative technologies including wearable sensors, micro-needles, and inhalable insulin. Advanced therapies, such as continuous glucose monitoring systems (CGMS), artificial pancreas, and insulin patches, are also employed to improve blood sugar level management that minimize the risks of diabetic-related complications. In addition, the procedure facilitates easy calculation of the dose volume, checking the blood glucose levels in real-time, and delivers insulin into the body painlessly, which, in turn, helps to maintain the dosage time. Some of the advantages of this therapy and drug delivery practice includes improved patient outcomes, enhanced treatment efficiency, and minimized burden of diabetes management for patients, leading to more targeted treatment plans.
The global market is primarily driven by the rising prevalence of diabetes, particularly type-2 diabetes, among the masses. This can be attributed to the increasing consumption of unhealthy diets, sedentary lifestyles and reduced physical activity. In line with this, the augmenting demand for personalized and patient-centric care according to individual needs, lifestyle, and treatment goals is resulting in a higher product uptake. Moreover, continual technological advancements, such as the development of smart insulin pens, closed-loop systems, and implantable devices with fewer side effects, is providing an impetus to the market. In addition to this, the increasing emphasis on minimally invasive and pain-free treatment options among individuals is also acting as a significant growth-inducing factor for the market. The market is further driven by the increasing healthcare expenditure, along with an enhanced focus on value-based medical care solutions. However, the growing cost restrains, lack of awareness and less variability in products in the developing regions are acting as major growth-restraining factors for the market. Conversely, the implementation of favorable government initiatives and reimbursement policies regarding preventive healthcare and early intervention is creating a positive outlook for the market. Apart from this, the growing geriatric population that is more susceptible to developing chronic diseases is impacting the market favorably. Some of the other factors contributing to the market include rapid urbanization, increasing awareness regarding the associated complications of traditional diabetes treatment, rising adoption of telehealth and digital health solutions, inflating disposable income levels and extensive research and development (R&D) activities conducted by key players.
IMARC Group provides an analysis of the key trends in each segment of the global next generation diabetes therapy and drug delivery market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product type, demographic, indication, and end user.
Inhalable Insulin
Oral Insulin
Insulin Patches
CGM Systems
Artificial Pancreas
The report has provided a detailed breakup and analysis of the global next generation diabetes therapy and drug delivery market based on the product type. This includes inhalable insulin, oral insulin, insulin patches, CGM systems, and artificial pancreas. According to the report, CGM systems represented the largest segment.
Adult Population (>14 Years)
Child Population (14 Years)
The report has provided a detailed breakup and analysis of the global next generation diabetes therapy and drug delivery market based on the demographic. This includes adult population (>14 years) and child population (14 years). According to the report, adult population (>14 years) represented the largest segment.
Type 1 diabetes
Type 2 diabetes
The report has provided a detailed breakup and analysis of the global next generation diabetes therapy and drug delivery market based on the indication. This includes type 1 diabetes, type 2 diabetes. According to the report, type 2 diabetes represented the largest segment.
Diagnostic/Clinics
Intensive Care Units (ICUs)
Home Healthcare
A detailed breakup and analysis of the global next generation diabetes therapy and drug delivery market based on the end user has also been provided in the report. This includes diagnostic/clinics, intensive care units (ICUs), and home healthcare. According to the report, diagnostic/clinics accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for next generation diabetes therapy and drug delivery. Some of the factors driving the North America next generation diabetes therapy and drug delivery market included the aging population, continual technological advancements, high healthcare expenditure, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global next generation diabetes therapy and drug delivery market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Dexcom Inc., Eli Lilly and Company, Enteris BioPharma Inc. (Swk Holdings Corporation), GlySens Incorporated, MannKind Corporation, Medtronic plc, Sanofi, Senseonics, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.